Key Highlights
- BioLineRx shares traded at $2.83, down 2.41% on the day.
- Phase 1/2 dosing for GLIX1 commenced, noted May 27, 2026.
- Preclinical data will be shared at ESMO, October 23-27, 2026.
- Phase 1 data from the trial are anticipated in the first half of 2027.
BioLineRx Ltd. (NASDAQ: BLRX) shares traded at $2.83, down 2.41% on the day, as the company continues to advance GLIX1 in glioblastoma, with Phase 1/2 dosing underway.
What Happened
Phase 1/2 study dosing commenced, noted May 27, 2026, with data from the Phase 1 portion of the trial anticipated in the first half of 2027.
Preclinical data is scheduled to be shared at the ESMO congress, held October 23-27, 2026. Earlier preclinical data, noted May 19, 2026, demonstrated GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses tested.
Market Reaction
Shares traded down 2.41% at $2.83, with BioLineRx's market capitalization at approximately $12.31 million, according to the disclosed pipeline database, positioning it among the smaller companies in the disclosed group.
Outlook
Phase 1 data from the ongoing trial is anticipated in the first half of 2027, with additional preclinical data set for presentation at ESMO in October 2026.
What is the status of BioLineRx's GLIX1 program?
Phase 1/2 dosing commenced in May 2026, with Phase 1 data anticipated in the first half of 2027.
What condition is GLIX1 being developed to treat?
It is being developed for glioblastoma.
What has preclinical data shown for GLIX1?
Preclinical data demonstrated robust, dose-dependent efficacy, with strong anti-tumor activity observed even at the lowest doses tested.






Please wait processing your request...